Navigation Links
Vanderbilt-Ingram Cancer Center launches online genetic research tool

Vanderbilt-Ingram Cancer Center (VICC) has launched the nation's first personalized cancer decision support tool, "My Cancer Genome," to help physicians and researchers track the latest developments in personalized cancer medicine and connect with clinical research trials for their patients.

This web-based information tool ( is designed to quickly educate clinicians on the rapidly expanding list of genetic mutations that impact different cancers and, at the same time, enable them to more easily research various treatment options based on specific mutations.

My Cancer Genome is the latest addition to VICC's Personalized Cancer Medicine Initiative, which was unveiled last year.

"Next-generation, or genetically-informed cancer medicine, holds the promise of tailoring anti-cancer treatment according to individual patient tumor characteristics," said William Pao, M.D., Ph.D., associate professor of Medicine and director of Personalized Cancer Medicine at VICC.

"Staying abreast of these fast-paced research changes may be difficult for time-pressed oncologists and medical caregivers. In particular, knowledge about rare variants found in cancers may be hard to track down, especially in busy clinics. We launched this web-based tool to enable a genetically-informed approach to cancer medicine that we believe can be more efficient and effective."

With just a few clicks, users can get up-to-date information on the clinical significance of specific mutations.

Here's how it works: A doctor receives tumor profiling results from the lab that show a mutation in a specific gene. The doctor remembers a little about the gene, but hasn't seen that result very often, as it is relatively uncommon.

Instead of having to search through a great deal of literature, the physician can log on to VICC's My Cancer Genome tool and, within a few minutes, find the latest information about the clinical implications of the gene, either by reading the summary version or delving further into the primary literature through web links. The physician can then recommend treatment that is currently available or refer the patient to a clinical trial that is testing a targeted therapy for that gene.

Finally, the patient also can go to the VICC website and learn more about their cancer by using the My Cancer Genome tool.

"We designed this online tool to be comprehensive, scalable and easy for clinicians to use," said Mia Levy, M.D., Ph.D., assistant professor of Biomedical Informatics and Medicine and Cancer Clinical Informatics Officer for VICC.

"This new online tool is already linked to Vanderbilt University Medical Center's StarPanel electronic medical record database to help our physicians make treatment decisions quickly, based on the best science available.

"Once we test a patient's tumor for specific mutations, the test results stay in a patient's medical record, so as new treatment options become available for each mutation, our physicians will have that information at their fingertips," Levy said.

The first two forms of cancer featured on VICC's My Cancer Genome information tool are lung cancer and melanoma, with plans to add content on breast, colon and other cancers in a few months.

"We envision that VICC's My Cancer Genome can become a global research and resource platform connecting the entire cancer community, including doctors, researchers, students, patients and caregivers.

"We will be reaching out in the future to encourage all stakeholders to contribute information so that we can improve information flow and accelerate the development of better personalized targeted therapy for all cancer patients," Pao said.


Contact: Dagny Stuart
Vanderbilt University Medical Center

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
3. The dietary supplement genistein can undermine breast cancer treatment
4. Saliva proteins could help detection of oral cancer
5. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
6. Breakthrough optical technology to assess colon cancer risk, accuracy
7. Breast cancer cells recycle to escape death by hormonal therapy
8. Nanodiamond drug device could transform cancer treatment
9. Second lumpectomy for breast cancer reduces survival rates
10. Study looks at psychological impact of gene test for breast cancer
11. SNM releases new fact sheet on breast cancer and molecular imaging
Post Your Comments:
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
(Date:10/27/2015)... 2015 Munich, Germany ... technology (ASGM) automatically maps data from mobile eye tracking ... , so that they can be quantitatively analyzed with ... Munich, Germany , October 28-29, 2015. SMI,s Automated ... mobile eye tracking videos created with SMI,s Eye ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh ... Insertion points for in-line sensors can represent a weak spot where leaking process ... series of retractable sensor housings , which are designed to tolerate extreme process ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Technologies, Inc., on being named to Deloitte's 2015 Technology Fast 500 list of ... OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device that speeds up orthodontic ...
(Date:11/24/2015)... 2015 Capricor Therapeutics, Inc. (NASDAQ: ... discovery, development and commercialization of first-in-class therapeutics, today announced ... is scheduled to present at the 2015 Piper Jaffray ... EST, at The Lotte New York Palace Hotel in ... . --> . ...
Breaking Biology Technology: